Skip to main content
Download PDF

Erratum to: Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years’ treatment

Orphanet Journal of Rare Diseases volume 11, Article number: 95 (2016) Cite this article

The Original Article was published on 29 September 2015

Erratum

Following the publication of our article “Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years’ treatment” by Kampmann et al. [1] we have become aware that the dose of agalsidase alfa was not reported.

Eligible patients had a Fabry disease diagnosis confirmed by enzyme assay (males) and/or DNA analysis (males and females), were aged ≥14 years at treatment start, and had received agalsidase alfa (Replagal®; Shire, Lexington, Massachusetts, USA) ERT at a dose of 0.2 mg/kg body weight every other week for approximately 10 years.

Reference

  1. Kampmann C, Perrin A, Beck M. Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years’ treatment. Orphanet J Rare Dis. 2015;10:125.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section Head for Congenital Heart Defects, Center for Pediatric and Adolescent Medicine, University Medical Center, University of Mainz, Langenbeckstr. 1, Mainz, DE-55101, Germany

    Christoph Kampmann

  2. Statistical Programmer, Rare Diseases Business Unit, Global Outcomes Research, Shire, Zug, Switzerland

    Amandine Perrin

  3. Professor Emeritus, Department of Pediatrics, University Medical Center, University of Mainz, Mainz, Germany

    Michael Beck

Authors
  1. Christoph Kampmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amandine Perrin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael Beck
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christoph Kampmann.

Additional information

The online version of the original article can be found under doi:10.1186/s13023-015-0338-2.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kampmann, C., Perrin, A. & Beck, M. Erratum to: Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years’ treatment. Orphanet J Rare Dis 11, 95 (2016). https://doi.org/10.1186/s13023-016-0482-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s13023-016-0482-3

Orphanet Journal of Rare Diseases

ISSN: 1750-1172